Table 2.
Baseline Characteristics
| Characteristics | Treatment Group | ||
|---|---|---|---|
| 20M | 100M | Total | |
| (n=15) | (n=15) | (n=30) | |
| Gender | |||
| Male | 12 (80.0) | 15 (100.0) | 27 (90.0) |
| Female | 3 (20.0) | 0 (0.0) | 3 (10.0) |
| Ethnicity | |||
| Hispanic or Latino | 2 (13.3) | 3 (20.0) | 5 (16.7) |
| Not Hispanic or Latino | 13 (86.7) | 12 (80.0) | 25 (83.3) |
| Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Not Answered | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Race | |||
| American Indian/Alaskan | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Asian | 0 (0.0) | 1 (6.7) | 1 (3.3) |
| Hawaiian/Pacific Islander | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Black or African American | 1 (6.7) | 0 (0.0) | 1 (3.3) |
| White | 14 (93.3) | 14 (93.3) | 28 (93.3) |
| More than One Race | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| History of Coronary Interventions | 15 (100.0) | 14 (93.3) | 29 (96.7) |
| Previously Referred for AICD Placement | 11 (73.3) | 12 (80.0) | 23 (76.7) |
| History of Atrial or Ventricular Arrhythmia | 5 (33.3) | 8 (53.3) | 13 (43.3) |
| History of Hypertension | 10 (66.7) | 7 (46.7) | 17 (56.7) |
| History of Congestive Heart Failure | 11 (73.3) | 12 (80.0) | 23 (76.7) |
| History of Valvular Heart Disease | 2 (13.3) | 2 (13.3) | 4 (13.3) |
| History of Smoking | 5 (33.3) | 12 (80.0) | 17 (56.7) |
| History of Diabetes | 3 (20.0) | 4 (26.7) | 7 (23.3) |
| Glomerular Filtration Rate (mL/min/1.73m2 ) | 70.0±24.4 | 79.2±20.4 | 74.6±22.6 |
| Age at injection (years) | 66.8±12.2 | 65.6±9.4 | 66.2±10.7 |
|
| |||
| Cardiac Function and Scar Size | |||
|
| |||
| Ejection Fraction (%) | 37.6 (24.3, 39.9) | 30.1 (22.3, 38.9) | 36.1 (24.3, 38.9) |
| End Systolic Volume (mL) | 140.3 (119.6, 262.5) | 177.3 (147.8, 249.4) | 168.8 (132.0,249.4) |
| End Diastolic Volume (mL) | 234.2 (191.8, 332.6) | 273.3 (234.1, 345.0) | 250.7 (214.6, 332.6) |
| Stroke Volume (mL) | 88.9±21.28 | 79.8±24.73 | 84.3±23.13 |
| End Diastolic Diameter (mm) | 58.3 (55.9, 72.5) | 64.3 (56.4, 67.3) | 60.9 (56.4, 67.3) |
| End Systolic Diameter (mm) | 52.4 (43.0, 58.8) | 53.7 (49.2, 57.5) | 52.8 (46.2, 57.5) |
| End-Diastolic Long Axis Diameter (mm) | 99.0±10.41 | 101.2±8.54 | 100.1±9.42 |
| Scar Size (g) | 17.9 (12.5, 23.1) | 16.2 (13.8, 24.3) | 17.1 (13.7, 23.9) |
| Scar Size / LV mass (%) | 9.9 (6.5, 16.6) | 9.7 (6.5, 12.3) | 9.8 (6.5, 14.4) |
|
| |||
| Functional Capacity and Quality of Life | |||
|
| |||
| NYHA Functional Class | |||
| I | 4 (26.7) | 6 (40.0) | 10 (33.3) |
| II | 8 (53.3) | 7 (46.7) | 15 (50.0) |
| III | 3 (20.0) | 1 (6.7) | 4 (13.3) |
| IV | 0 (0.0) | 1 (6.7) | 1 (3.3) |
| Peak VO2 (mL/kg/min) | 15.8±5.1 | 16.7±4.5 | 16.3±4.8 |
| Six Minute Walk Test (m) | 398.7±111.6 | 434.9±120.0 | 416.8±115.4 |
| MLHFQ score | 29.0 (21.0, 52.0) | 35.0 (6.0, 60.0) | 31.5 (9.0, 55.0) |
| FEV1 (%) | 72.7±15.1 | 76.9±15.5 | 74.8±15.2 |
| Pro-BNP (pg/mL) | 532.3 (373.5, 1530.0) | 377.7 (212.0,1246.0) | 443.9 (304.6, 1422.0) |
| Pro-BNP (log pg/mL) | 6.5±0.90 | 6.2±1.10 | 6.3±1.00 |
| TNFα (pg/mL) | 9.0 (5.7, 13.8) | 14.6 (11.7, 16.3) | 12.9 (7.6, 15.1) |
Values are mean±standard deviation, n (%), or median (interquartile range).